A comprehensive, no-cost resource for covered entities preparing for 2026.
The Inflation Reduction Act’s (IRA) Maximum Fair Price (MFP) requirements and HRSA’s 340B Rebate Model Pilot Program, effective in 2026, introduce major changes to drug pricing and manufacturer rebate obligations.
This guide consolidates federal updates, operational workflows, rebate mechanics, data requirements, and implementation best practices—all in one place. Virtue created this resource to help covered entities prepare early, understand compliance requirements, and make informed decisions—whether handling the work internally or partnering with expert support. Read More >
